Clinical Trials Browser

Immunoglobulin Light-chain Amyloidosis, Anemia, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Mycosis Fungoides, Precancerous Conditions, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell

NCT00327535 2016-08-11

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Phase 2 Completed

153 enrolled

Classical hematology

Anemia

NCT00077311 2016-06-30

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

160 enrolled

Classical hematologyThoracic

Adenocarcinoma of Lung, Anemia, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutropenia, Drug-Related Side Effects and Adverse Reactions

NCT00401544 2014-01-29

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Phase 2 Completed

243 enrolled 26 charts

Classical hematology

Anemia, Neoplasms

NCT00144131 2013-05-24

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Phase 2 Completed

750 enrolled

Classical hematology

Anemia, Neoplasms

NCT00111462 2013-05-08

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Phase 2 Completed

Classical hematology

Anemia, Neoplasms

NCT00540696 2013-04-26

Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

Phase 2 Completed

300 enrolled

Classical hematology

Anemia

NCT00359840 2012-08-31

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Phase 2 Completed

120 enrolled

Classical hematology

Anemia

NCT00239239 2010-03-05

Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

Phase 2 Completed

44 enrolled

Classical hematology

Anemia, Neoplasms

NCT00261313 2010-02-26

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

Phase 2 Completed

80 enrolled

Breast

Breast Neoplasms

NCT00036023 2009-05-11

Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies

Phase 2 Completed

BreastLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00120705 2009-03-25

Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy

Phase 2 Completed

204 enrolled

Classical hematology

Anemia, Neoplasms

NCT00095277 2009-03-13

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Phase 2 Completed

220 enrolled

Classical hematologyPlasma cell

Anemia, Neoplasms, Plasma Cell

NCT00120679 2007-12-24

Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy

Phase 2 Completed

Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung

NCT00120692 2007-12-24

Treatment for Patients Suffering From Anemia Due to Chemotherapy

Phase 2 Completed

BreastClassical hematology

Anemia, Breast Neoplasms

NCT00121030 2007-12-24

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

Phase 2 Completed

Classical hematologyGynecologic

Anemia, Genital Neoplasms, Female, Ovarian Neoplasms, Uterine Neoplasms

NCT00245895 2007-11-29

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

Phase 2 Completed

20 enrolled

Classical hematologyGenitourinary

Anemia, Prostatic Neoplasms

Clinical Trials

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Erythropoietin for Management of Anemia Caused by Chemotherapy

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Darbepoetin Alfa With or Without Intravenous (IV) Iron

Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies

Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy

Treatment for Patients Suffering From Anemia Due to Chemotherapy

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.